Erianin mitigates diabetic cardiomyopathy via adenosine monophosphate-activated protein kinase-nuclear factor erythroid 2-related factor 2-heme oxygenase-1 pathway activation

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-10)

Tables (1-1)

Sum=184

Publishing Process of This Article

Item

Count

Browse

Download

Sum=0

Jun 15, 2025 (publication date) through Jun 16, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Diabetes. Jun 15, 2025; 16(6): 103685
Published online Jun 15, 2025. doi: 10.4239/wjd.v16.i6.103685

Full Size Figure Download Figure

Figure 2 Hematoxylin-eosin staining of myocardial tissue in type 2 diabetes mellitus mice (× 200). L: Low; M: Middle; H: High.

Citation: Chen JH, Dai XC, Quan ZJ, Liu XY. Erianin mitigates diabetic cardiomyopathy via adenosine monophosphate-activated protein kinase-nuclear factor erythroid 2-related factor 2-heme oxygenase-1 pathway activation. World J Diabetes 2025; 16(6): 103685
URL: https://www.wjgnet.com/1948-9358/full/v16/i6/103685.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i6.103685